Liposomal vasoactive intestinal peptide for lung application: Protection from proteolytic degradation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 153-164

  Stark, Brigitte ^a   Andreae, Fritz ^b   Mosgoeller, Wilhelm ^c   Edetsberger, Michael ^d   Gaubitzer, Erwin ^d   Koehler, Gottfried ^d   Prassl, Ruth ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b piCHEM Research and Development   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Liposomes; Proteolytic degradation; Pulmonary delivery; VIP

Indexed keywords

DISTEARYLPHOSPHATIDYLETHANOLAMINE; FLUORESCENT DYE; LIPOSOME; LUNG SURFACTANT; LYSOSTEARYLPHOSPHATIDYLGLYCEROL; MACROGOL; OLEOYLPALMITOYLLECITHIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG STABILITY; FIBEROPTIC BRONCHOSCOPY; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID MEMBRANE; LUNG LAVAGE; MASS SPECTROMETRY; PROTEIN DEGRADATION;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HUMANS; LIPIDS; LIPOSOMES; LUNG; MALE; PARTICLE SIZE; PEPTIDE HYDROLASES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY SYSTEM AGENTS; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION; VASODILATOR AGENTS;

EID: 50149098762     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.04.015     Document Type: Article

References (60)

1. Refai E., Jonsson C., Andersson M., Jacobsson H., Larsson S., Kogner P., and Hassan M. Biodistribution of liposomal 131I-VIP in rat using gamma camera. Nucl. Med. Biol. 26 (1999) 931-936
2. Sethi V., Onyuksel H., and Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 391 (2005) 377-395
3. Groneberg D.A., Rabe K.F., Wagner U., and Fischer A. Vasoactive intestinal polypeptide in the respiratory tract: physiology and pathophysiology. Pneumologie 58 (2004) 330-338
4. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur. J. Pharmacol. 533 (2006) 182-194
5. Gololobov G., Noda Y., Sherman S., Rubinstein I., Baranowska-Kortylewicz J., and Paul S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285 (1998) 753-758
6. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., and Block L.H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111 (2003) 1339-1346
7. Gao X.P., Noda Y., Rubinstein I., and Paul S. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure. Life Sci. 54 (1994) 247-252
8. Ganea D., and Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral. Biol. Med. 13 (2002) 229-237
9. Dejda A., Sokolowska P., and Nowak J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep. 57 (2005) 307-320
10. Ollerenshaw S., Jarvis D., Woolcock A., Sullivan C., and Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N. Engl. J. Med. 320 (1989) 1244-1248
11. Surrenti C., Renzi D., Garcea M.R., Surrenti E., and Salvadori G. Colonic vasoactive intestinal polypeptide in ulcerative colitis. J. Physiol. Paris 87 (1993) 307-311
12. Dorfmuller P., Perros F., Balabanian K., and Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22 (2003) 358-363
13. Pietra G.G. The Pathology of Primary Pulmonary Hypertension. In: Rubin L.J., and Rich S. (Eds). Primary Pulmonary Hypertension (1997), Marcel Dekker, New York 19-61
14. Tam E.K., Franconi G.M., Nadel J.A., and Caughey G.H. Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am. J. Respir. Cell Mol. Biol. 2 (1990) 449-452
15. Tam E.K., and Caughey G.H. Degradation of airway neuropeptides by human lung tryptase. Am. J. Respir. Cell Mol. Biol. 3 (1990) 27-32
16. Taylor K.M.G., and Farr S.J. Liposomes for pulmonary drug delivery. In: Gregoriadis G., Florence A.T., and Patel H.M. (Eds). Liposomes in Drug Delivery (1993), Harwood Academic Publishers, Chur 95-110
17. Mitra R., Pezron I., Li Y., and Mitra A.K. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int. J. Pharm. 217 (2001) 25-31
18. Suzuki H., Gao X.P., Olopade C.O., and Rubinstein I. Neutral endopeptidase modulates VIP-induced vasodilation in hamster cheek pouch vessels in situ. Am. J. Physiol. 271 (1996) 393-397
19. Goetzl E.J., Sreedharan S.P., Turck C.W., Bridenbaugh R., and Malfroy B. Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11). Biochem. Biophys. Res. Commun. 158 (1989) 850-854
20. Lilly C.M., Drazen J.M., and Shore S.A. Peptidase modulation of airway effects of neuropeptides. Proc. Soc. Exp. Biol. Med. 203 (1993) 388-404
21. Bolin D.R., Michalewsky J., Wasserman M.A., and O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37 (1995) 57-66
22. Ikezaki H., Paul S., Alkan-Onyuksel H., Patel M., Gao X.P., and Rubinstein I. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch. Am. J. Physiol. 275 (1998) 56-62
23. Sejourne F., Rubinstein I., Suzuki H., and Alkan-Onyuksel H. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm. Res. 14 (1997) 362-365
24. Lasic D.D. Novel applications of liposomes. Trends Biotech. 16 (1998) 307-321
25. Lian T., and Ho R.J. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90 (2001) 667-680
26. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
27. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
28. Kellaway I.W., and Farr S.J. Liposomes as drug delivery systems to the lung. Adv. Drug Deliv. Rev. 5 (1990) 149-161
29. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., and Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88 (1991) 11460-11464
30. Allen T.M., and Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068 (1991) 133-141
31. Woodle M.C., and Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1113 (1992) 171-199
32. Huang M., and Rorstad O.P. VIP receptors in mesenteric and coronary arteries: a radioligand binding study. Peptides 8 (1987) 477-485
33. Rubinstein I., Patel M., Ikezaki H., Dagar S., and Onyuksel H. Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin. Peptides 20 (1999) 1497-1501
34. Suzuki H., Noda Y., Paul S., Gao X.P., and Rubinstein I. Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo. Life Sci. 57 (1995) 1451-1457
35. Waldrep J.C. New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. Drugs Today (Barc.) 34 (1998) 549-561
36. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7 (2005) 20-41
37. Niven R. Modulated drug therapy with inhalation aerosols. In: Hickey A.J. (Ed). Pharmaceutical Inhalation Aerosols Technology (2003), Marcel Dekker, New York 551-570
38. Anabousi S., Kleemann E., Bakowsky U., Kissel T., Schmehl T., Gessler T., Seeger W., Lehr C.M., and Ehrhardt C. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J. Nanosci. Nanotechnol. 6 (2006) 3010-3016
39. Wattiez R., and Falmagne P. Proteomics of bronchoalveolar lavage fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815 (2005) 169-178
40. Vermehren C., Frokjaer S., Aurstad T., and Hansen J. Lung surfactant as a drug delivery system. Int. J. Pharm. 307 (2006) 89-92
41. Wu J., Kobayashi M., Sousa E.A., Liu W., Cai J., Goldman S.J., Dorner A.J., Projan S.J., Kavuru M.S., Qiu Y., and Thomassen M.J. Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol. Cell. Proteomics 4 (2005) 1251-1264
42. Plymoth A., Lofdahl C.G., Ekberg-Jansson A., Dahlback M., Lindberg H., Fehniger T.E., and Marko-Varga G. Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 3 (2003) 962-972
43. Notter R.H. Lung surfactant. Basic Science and Clinical Applications (2000), Marcel Dekker, Inc., New York 1-444
44. Hills B.A. Surface-active phospholipid: a Pandora's box of clinical applications. Part I. The lung and air spaces. Intern. Med. J. 32 (2002) 170-178
45. Noel-Georis I., Bernard A., Falmagne P., and Wattiez R. Database of bronchoalveolar lavage fluid proteins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 771 (2002) 221-236
46. Stark B., Debbage P., Andreae F., Mosgoeller W., and Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim. Biophys. Acta 1768 (2007) 705-714
47. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 234 (1959) 466-468
48. Chen Y., Muller J.D., Berland K.M., and Gratton E. Fluorescence fluctuation spectroscopy. Methods 19 (1999) 234-252
49. Chen Y., Muller J.D., So P.T., and Gratton E. The photon counting histogram in fluorescence fluctuation spectroscopy. Biophys. J. 77 (1999) 553-567
50. Edetsberger M., Gaubitzer E., Valic E., Waigmann E., and Kohler G. Detection of nanometer-sized particles in living cells using modern fluorescence fluctuation methods. Biochem. Biophys. Res. Commun. 332 (2005) 109-116
51. Hess S.T., Huang S., Heikal A.A., and Webb W.W. Biological and chemical applications of fluorescence correlation spectroscopy: a review. Biochemistry 41 (2002) 697-705
52. Kask P., Palo K., Ullmann D., and Gall K. Fluorescence-intensity distribution analysis and its application in biomolecular detection technology. Proc. Natl. Acad. Sci. USA 96 (1999) 13756-13761
53. Muller J.D., Chen Y., Ruan Q.Q., Mantulin W.W., and Gratton E. Resolving heterogeneuos sample populations with the photon counting histogram method. Biophys. J. 76 1 Pt 2 (1999) A359
54. Schwille P., Haupts U., Maiti S., and Webb W.W. Molecular dynamics in living cells observed by fluorescence correlation spectroscopy with one- and two-photon excitation. Biophys. J. 77 (1999) 2251-2265
55. Kask P., Palo K., Mets U., Cole M., and Gall M.K. Fluorescence intensity distribution analysis (FIDA) and related fluorescence fluctuation techniques: theory and practice. In: Krayenhof R., Visser A.J.W.G., and Gerrritsen H.C. (Eds). Fluorescence Spectroscopy, Imaging and Probes (2002), Springer 154-171
56. Robinson R.M., Blakeney Jr. E.W., and Mattice W.L. Lipid-induced conformational changes in glucagon, secretin, and vasoactive intestinal peptide. Biopolymers 21 (1982) 1228-1271
57. Harris J.M., Martin N.E., and Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40 (2001) 539-551
58. Nucci M.L., Shorr R., and Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug. Deliv. Rev. 6 (1991) 133-151
59. Delgado C., Francis G.E., and Fisher D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9 (1992) 249-304
60. Stiuso P., Marabotti A., Facchiano A., Lepretti M., Dicitore A., Ferranti P., and Carteni M. Assessment of the conformational features of vasoactive intestinal peptide in solution by limited proteolysis experiments. Biopolymers 81 (2006) 110-119